Cover Image
市場調查報告書

間質幹細胞的全球市場

Mesenchymal Stem Cells

出版商 Global Industry Analysts, Inc. 商品編碼 297189
出版日期 內容資訊 英文 184 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
間質幹細胞的全球市場 Mesenchymal Stem Cells
出版日期: 2016年09月01日 內容資訊: 英文 184 Pages
簡介

本報告提供間質幹細胞的全球市場分析。還有關於美國、加拿大、日本、歐洲、亞太地區及其他地區的各地區各種綜合分析、從2009年到2018年的各年估計與預測。加上含主要企業與利基企業的51家公司簡介,為您概述為以下內容。

第1章 序、調查方法及產品定義

  • 調查的可靠性和報告的規定
  • 免責聲明
  • 資料的解釋與報告層級
  • 產品定義和調查範圍

第2章 摘要整理

  • 市場概況
    • 間質幹細胞 - 醫學中下個大飛躍
    • 現在及未來分析
    • 間質幹細胞療法現況與未來
    • 間質幹細胞治療:主要的開發中產品的清單(2013年12月現在)
    • 「現成」間質幹細胞的普及企業化帶著現實味
    • 軟體企業在這個熱潮努力賺錢
  • 推動市場要素、趨勢及課題
    • 人口的高齡化促進間質幹細胞療法的需求
    • 對於胚胎幹細胞研究相關的議論永不停止,成體幹細胞療法搭上成長軌道
    • 成體幹細胞及胚胎幹細胞 - 比較
    • 間質幹細胞 對 胚胎以及誘導性多功能幹細胞
    • 間質幹細胞療法不受胚胎幹細胞適用的倫理問題的影響
    • 間質幹細胞 - 可用於「標靶藥物傳輸」的搬運方式
    • 生物內特性相關漏洞促進療法的進步
    • 擋住間質幹細胞市場的大的課題
  • 幹細胞市場 - 宏觀觀點
    • 間質幹細胞主導
    • 幹細胞研究急速前進著
    • 到現在為止主要的成果
    • 幹細胞研究領域主要的歷史性的事項
    • 限制幹細胞研究的法律 - 法規概要
    • 主要國家的幹細胞研究的法律規章
    • 市場動態及趨勢
    • 北美支配全球幹細胞研究
    • 幹細胞療法從概念持續轉移到現實
    • 幹細胞成為醫學上極大可能性的徵兆
    • 對已經期待已久的幹細胞療法的要求
    • 韓國實施全球第一個體性幹細胞為基礎的治療
    • 對幹細胞市場的主要規定
    • 幹細胞旅遊觀光事業- 熱潮還是滅亡根源?
    • 畸形腫 - 已經不是幹細胞治療開發的障礙
    • 美國和日本在幹細胞專利上領先於歐洲
    • 抑制幹細胞治療的開發課題
  • 主要的幹細胞變形概況
    • 成體幹細胞
    • 低風險的投資
    • 成體幹細胞進一步聚集研究用投資
    • 多樣性低 - 成體幹細胞的主要阻礙因素
    • 造血幹細胞 - 取得不朽的成功
    • 阻礙因素
    • 誘導性多功能幹細胞 - ESC的替代
    • iPS的發現
    • 醫藥品開發 - IPS的主要應用
    • 再生醫療的iPS的使用
    • iPS細胞庫的確立
    • 難治性及先天性疾病治療
    • 改變醫學的胚胎幹細胞
    • 倫理問題和技術的門檻使hESC研究踏步
    • 安全性和有效性的資料的不足 - 主要疑慮
  • 各應用領域的間質幹細胞研究
    • 整形外科的間質幹細胞
    • 整形手術用間質幹細胞為基礎的模式
    • 對需要療法領域的間質幹細胞的經銷
    • 骨關節炎治療的間質幹細胞
    • 類風濕性關節炎治療的間質幹細胞
    • 癌症治療的間質幹細胞
    • 肝臟學的間質幹細胞
    • 神經學的間質幹細胞
    • 放射治療的間質幹細胞
    • 糖尿病治療的間質幹細胞
    • 自體免疫疾病治療的間質幹細胞
    • 卵巢早衰治療的間質幹細胞
    • 基因治療的間質幹細胞
    • 肺部疾病治療的間質幹細胞
    • 結腸修復的間質幹細胞
    • 腎修復的間質幹細胞
  • 產品概要
    • 間質幹細胞(MSC)- 序
    • 歷史
    • 同類間質幹細胞是什麼?
    • 為何間質幹細胞那麼受歡迎?
    • 間質幹細胞的幾個主要供給來源
    • 骨髓
    • 瓦頓氏膠及臍帶血
    • 脂肪組織
    • 滋養層組織
    • 羊水
    • 開發下頜智齒的牙蕾
    • 間質幹細胞治療的機制
    • 間質幹細胞的重要功能
    • 形態學
    • 識別/檢測
    • 分化能力
    • 免疫疾病調節作用
    • 培養
    • 臨床用途
    • 臨床等級間質幹細胞的生產
    • 間質幹細胞的缺點
  • 產品的創新與發售
    • Vitro Biopharma 推出一連串新的幹細胞產品
    • Rainbow Scientific Biological Industries發售幹細胞培養系統
    • LABS推出生技藥品篩檢用新的實驗室篩檢
    • Vitro Diagnostics 推出一連串新產品
    • IntelliCell BioSciences 從非生物脂肪組織開發到基質血管成分細胞
    • Vitro Diagnostics 推出細胞治療的新產品
    • Vitro Diagnostics 推出複數的幹細胞產品
  • 最近的產業趨勢
    • Life Technologies與Harvard University締結專利及幹細胞共同研究契約
    • Stemedica Cell Technologies 與 Life Technologies 締結全世界的銷售契約
    • ThermoGenesis Helmer 將ThermoLine的資產賣給Scientific
    • Athersys接受MHRA的認證,以擴大缺血性中風的MultiStem細胞療法的第二階段臨床試驗
    • Osiris Therapeutics 接受來自EMA的Prochymal®孤兒藥指定
    • 其他31個案例
  • 主要企業
    • Aastrom Biosciences, Inc. (美國)
    • Cell Applications, Inc (美國)
    • Celprogen, Inc (美國)
    • Cyagen Biosciences Inc (美國)
    • EMD Millipore Corporation (美國)
    • 其他15家公司
  • 全球市場展望

第3章 市場

  • 美國
  • 加拿大
  • 日本
  • 歐洲
  • 亞太地區
  • 其他地區

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: MCP-7815

This report analyzes the worldwide markets for Mesenchymal Stem Cells in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 47 companies including many key and niche players such as -

Aastrom Biosciences, Inc.
Cell Applications, Inc.
Celprogen, Inc.
Cyagen Biosciences Inc.
MilliporeSigma

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

  • Study Reliability and Reporting Limitations
  • Disclaimers
  • Data Interpretation & Reporting Level
    • Quantitative Techniques & Analytics
  • Product Definitions and Scope of Study

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

  • Mesenchymal Stem Cells Market on a Rapid Growth Path
  • Current and Future Analysis
  • The Present and Future of MSC Therapies
  • Select MSC-based Therapeutics
  • Mesenchymal Stem Cell Research
    • Table 1: Mesenchymal Stem Cells-based (MSCs) Clinical Trials by Region (2015) (includes corresponding Graph/Chart)
  • Top 10 Countries Conducting Mesenchymal Stem Cells-based (MSCs) Clinical Trials 2015
    • Table 2: China Leads the MSC-based Clinical Trials: 2010-2015 (includes corresponding Graph/Chart)
    • Table 3: China's MSC-based Clinical Trials by Phase: 2015 (includes corresponding Graph/Chart)
    • Table 4: China's MSC-based Clinical Trials by Source: 2015 (includes corresponding Graph/Chart)
    • Table 5: China's MSC-based Clinical Trials by Indication: 2015 (includes corresponding Graph/Chart)
  • MSCs are Being Explored for Several New Treatment Possibilities
  • Widespread Commercialization of 'Off-the-Shelf' MSCs to Become a Reality
  • Software Companies Endeavour to Cash in on the Boom

2. MARKET DRIVERS, TRENDS & ISSUES

  • Development of Regenerative Medicine Accelerates Demand for MSCs
    • Table 6: Global Regenerative Medicines Market by Category (2015): Percentage Breakdown for Biopharmaceuticals, Cell and Tissue-Based Therapies, and Regenerative Devices & Compounds (includes corresponding Graph/Chart)
  • Ageing Demographics to Drive Demand for Mesenchymal Stem Cell Therapies
  • Global Aging Population Statistics - Opportunity Indicators
    • Table 7: Elderly Population (60+ Years) as a Percentage of Total Population (2015 & 2050) (includes corresponding Graph/Chart)
    • Table 8: Global Aging Population in Select Regions/Countries: Population of 60+ Individuals in '000s and as a Percentage of Total Population for 2015 & 2050 (includes corresponding Graph/Chart)
    • Table 9: Life Expectancy at Age 60 and 80 Years - (2010-2015), (2020-2025) & (2045-2050) (includes corresponding Graph/Chart)
    • Table 10: Life Expectancy for Select Countries in Number of Years: 2015E (includes corresponding Graph/Chart)
  • Growing Prevalence of Chronic Diseases Propels Demand for Mesenchymal Stem Cells
  • Key Disease Statistics - Opportunity Indicators
    • Table 11: Worldwide Incidence of Cancer (2012, 2020 & 2030): Number of New Cases Diagnosed (includes corresponding Graph/Chart)
    • Table 12: World Cancer Incidence by Geographic Region and Gender (2012): Number of New Cancer Cases Reported (in Thousands) for Asia-Oceania, Europe, North America, Latin America & the Caribbean, and Africa (includes corresponding Graph/Chart)
    • Table 13: Fatalities by Heart Conditions - Estimated Percentage Breakdown for Cardiovascular Disease, Ischemic Heart Disease, Stroke, and Others (includes corresponding Graph/Chart)
    • Table 14: Global Annual Medical Cost of CVD in US$ Billion (2010-2030) (includes corresponding Graph/Chart)
  • Growing Volume of Orthopedic Procedures: An Opportunity for the MSC Market
    • Table 15: Global Orthopedic Market by Segment (2015): Percentage Breakdown of Value Sales for Extremities, Hips, Knees, Orthobiologics, Spine, Trauma and Others (includes corresponding Graph/Chart)
  • Adult Stem Cell Therapies on Growth Trajectory, as Controversies Continue to Haunt Embryonic Stem Cell Research
  • Adult Stem Cells and Embryonic Stem Cells - A Comparison
  • MSCs versus Embryonic or Induced Pluripotent Stem Cells
  • MSC Therapies - Immune to Ethical Issues Applicable to Embryonic Stem Cells
  • MSCs - A Potential Vehicle for 'Targeted Drug Delivery'
  • Stem Cell Based Bone Grafts: Promising Growth Ahead
  • Loopholes Associated with In Vivo Properties Constrain Therapeutic Advancements
  • Major Challenges Confronting Mesenchymal Stem Cell Market
  • Allogeneic MSCs - Offering Promise in Immunosuppressive and Tissue Repair Therapy
  • Administration Route Determines the Effectiveness of MSCs

3. REVIEW OF SELECT MAJOR STEM CELL VARIANTS

  • Adult Stem Cells
  • A Low Risk Investment
  • Adult Stem Cells Garner More Investments for Research
  • Low Versatility - A Major Limiting Factor for Adult Stem Cells
  • Hematopoietic Stem Cells - Enjoying Enduring Success
  • Restraining Factors
  • Induced Pluripotent Stem Cells - An Alternative to ESCs
  • A Peek into the Discovery of iPS
  • Drug Development - A Major Application for iPS
  • Use of iPS for Regenerative Medicine
  • Establishing iPS Cell Banks
  • Intractable and Congenital Disease Treatments
  • Embryonic Stem Cells to Transfigure Medicine
  • Ethical Issues and Technical Hurdles Bog Down hESC Research
  • Lack of Safety and Efficacy Data - A Key Concern

4. MESENCHYMAL STEM CELL RESEARCH BY APPLICATION

  • Mesenchymal Stem Cells in Orthopedics
  • MSC based Models for Orthopedic Repair
  • Delivery of MSCs to Regions Requiring Therapy
  • MSCs in the Treatment of Osteoarthritis
  • MSCs in the Treatment of Rheumatoid Arthritis
  • MSCs in Cancer Treatment
  • MSCs in Hepatology
  • MSCs in Neurology
  • MSCs in Cardiology
  • MSCs in Radiotherapy
  • MSCs in the Treatment of Diabetes
  • MSCs in the Treatment of Autoimmune Diseases
  • MSCs in Treatment of Premature Ovarian Failure
  • MSCs for Gene Therapy
  • MSC Therapy in the Treatment of Lung Diseases
  • MSCs for Treating Liver Disease
  • MSCs for Treating Multiple Sclerosis-Phase II Clinical Trial Completed in the US (2016)
  • MSCs in Colon Repair
  • MSCs in Kidney Repair

5. PRODUCT OVERVIEW

  • Mesenchymal Stem Cells (MSCs) - An Introduction
  • History
  • What Are Allogeneic Mesenchymal Stem Cells?
  • Some Major Sources of Mesenchymal Stem Cells
  • Bone Marrow
  • Wharton's Jelly and Umbilical Cord Blood
  • Adipose Tissue
  • Trophoblastic Tissues
  • Amniotic Fluid
  • Developing Tooth Bud of Mandibular Third Molar
  • Mechanism of Mesenchymal Stem Cell Therapy
  • Important Features of Mesenchymal Stem Cells
  • Morphology
  • Identification/Detection
  • Differentiation Capacity
  • Immuno-modulatory Effects
  • Culturing
  • Clinical Use
  • Production of Clinical-Grade MSCs
  • Drawbacks of MSCs

6. RECENT INDUSTRY ACTIVITY

  • JCR Pharmaceuticals Develops TEMCELL HS
  • Stemedica Receives FDA Approval for Phase Iia Clinical Study for Traumatic Brain Injury
  • PuRec Announces Plans to Produce MSCs/RECs
  • Stemedica Enrolls into Phase I/IIa Clinical Study for Ischemic Stroke
  • JCR Pharmaceuticals Receives Pricing Notification
  • JCR Pharmaceuticals Awaits Approval for JR-031
  • Stemedica Receives FDA's Approval for Phase Iia Clinical Study
  • Mesoblast Announces Plans to Introduce Stem Cell Therapy Product
  • Stemedica Receives Patent
  • Stem Cell and Cancer Institute Receives IND approval
  • Thermo Fisher Scientific Takes Over Life Technologies

7. FOCUS ON SELECT PLAYERS

  • Cell Applications, Inc. (US)
  • Celprogen, Inc. (US)
  • Cyagen Biosciences, Inc. (US)
  • MilliporeSigma (US)
  • Genlantis, Inc. (US)
  • Thermo Fischer Scientific, Inc. (US)
  • Lonza Group (Switzerland)
  • Mesoblast Limited (Australia)
  • Neuromics (US)
  • Orthofix International N.V. (Curacao)
  • PromoCell GmbH (Germany)
  • R&D Systems, Inc. (US)
  • ScienCell Research Laboratories (US)
  • Stemcell Technologies Inc (Canada)
  • Stemedica Cell Technologies, Inc. (US)
  • Trevigen, Inc. (US)
  • Vericel Corporation (US)
  • Vitro Biopharma (US)

8. GLOBAL MARKET PERSPECTIVE

    • Table 16: World Recent Past, Current and Future Analysis for Mesenchymal Stem Cells by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2015 Through 2022 (includes corresponding Graph/Chart)
    • Table 17: World Historic Review for Mesenchymal Stem Cells by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2009 Through 2014 (includes corresponding Graph/Chart)
    • Table 18: World 14-Year Perspective for Mesenchymal Stem Cells by Geographic Region - Percentage Breakdown of Annual Revenues for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

III. MARKET

1. THE UNITED STATES

  • A. Market Analysis
    • Rapidly Ageing Population: A Major Driving Demand for MSC based Therapies
    • Table 19: North American Elderly Population by Age Group (1975-2050) (includes corresponding Graph/Chart)
    • Increasing Incidence of Chronic Diseases Drives Focus onto MSCs
    • Table 20: CVD in the US: Cardiovascular Disease Prevalence in Adults by Gender & Age Group (includes corresponding Graph/Chart)
    • Table 21: New Cancer Cases in Males in US by Body Site (2014) (includes corresponding Graph/Chart)
    • Table 22: New Cancer Cases in Females in US by Body Site (2014) (includes corresponding Graph/Chart)
    • Arthritis
    • Table 23: % of Population Diagnosed with Arthritis by Age Group (includes corresponding Graph/Chart)
    • Prochymal Obtains Fast Track Designation from FDA
    • MSCs for Treating Multiple Sclerosis-Phase II Clinical Trial Completed in the US
    • Rising Governmental Investments in Stem Cell Therapies - A Growth Booster
    • FDA Issues Warning Against Illegal Stem Cell Therapies
    • US Regulates Stem Cells as Drugs
    • Federal Law on Stem Cells in the US
    • NIH at the Forefront of Research Funding
    • NIH Guidelines on Stem Cell Research Funding
    • Bans and Restrictions on Stem Cell Research
    • American Type Culture Collection Inc (ATCC) - A Major Non-Profit Organization
    • Strategic Corporate Developments
    • Select Key Players
  • B. Market Analytics
    • Table 24: The US Recent Past, Current and Future Analysis for Mesenchymal Stem Cells Analyzed with Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 25: The US Historic Review for Mesenchymal Stem Cells Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

2. CANADA

  • A. Market Analysis
    • Current and Future Analysis
    • Prochymal - Canada's First MSC-based Therapy
    • Stemcell Technologies Inc - A Key Player
  • B. Market Analytics
    • Table 26: Canadian Recent Past, Current and Future Analysis for Mesenchymal Stem Cells Analyzed with Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 27: Canadian Historic Review for Mesenchymal Stem Cells Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

3. JAPAN

  • A. Market Analysis
    • Current and Future Analysis
    • Increasing Demand for Regenerative Medicine in Geriatric Healthcare and Cancer Care to Drive Demand for Mesenchymal Stem Cells
    • Table 28: Japanese Elderly (65+ Years) Population: 2000-2020 (includes corresponding Graph/Chart)
    • Table 29: Cancer Related Deaths by Age Group in Japan (2013) (includes corresponding Graph/Chart)
    • New Regulation for Accelerated Stem Cell Approval and Its Impact on Stem Cells Product Market
    • Strategic Corporate Development
  • B. Market Analytics
    • Table 30: Japanese Recent Past, Current and Future Analysis for Mesenchymal Stem Cells Analyzed with Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 31: Japanese Historic Review for Mesenchymal Stem Cells Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

4. EUROPE

  • A. Market Analysis
    • Current and Future Analysis
    • Ageing Population to Drive Demand for MSC based Therapies
    • Table 32: European Aging Population by Age Group: 1975-2050 (includes corresponding Graph/Chart)
    • Table 33: European Country-wise Statistics of 60+ Population as % of Total Population: 2013 (includes corresponding Graph/Chart)
    • Cancer in Europe: Key Statistics
    • Table 34: Number of New Cancer Cases in Europe: 2012-2030 (includes corresponding Graph/Chart)
    • Legislations on Stem Cell Research and Therapy in the EU
    • Unproven Stem Cell Therapies Receive Government Backing in the EU?
    • Scientists and Government Tussle over Safety of Stamina Foundation's MSC Therapy in Italy
    • Stem Cell Clinics Shut Down in Germany due to Malpractices
    • Key Players
  • B. Market Analytics
    • Table 35: European Recent Past, Current and Future Analysis for Mesenchymal Stem Cells Analyzed with Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 36: European Historic Review for Mesenchymal Stem Cells Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

5. ASIA-PACIFIC

  • A. Market Analysis
    • Current and Future Analysis
    • Overview of Select Countries
      • Australia
      • Stem Cell Tourism - A Popular Trend in Australia
      • South Korea
      • South Korea Pacing towards Regaining Lost Glory in Stem Cell Research
      • South Korea Upbeat on Stem Cell Therapy Market Potential
      • India
      • An Outline of the Stem Cell Research Structure in India
    • Table 37: Indian Adult Stem Cell Research (2012): Percentage Share Breakdown by Type (includes corresponding Graph/Chart)
      • A Regulatory Picture of the Indian Stem Cell Research and Therapy
      • Adult Stem Cells - A Highly Money-Spinning Market
      • Indians 'Bank' on Dental Stem Cells
      • New Zealand
      • Stem Cell Research Scenario in New Zealand
    • Product Launches
    • Key Players
  • B. Market Analytics
    • Table 38: Asia-Pacific Recent Past, Current and Future Analysis for Mesenchymal Stem Cells Analyzed with Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 39: Asia-Pacific Historic Review for Mesenchymal Stem Cells Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

6. REST OF WORLD

  • A. Market Analysis
    • Current and Future Analysis
    • Stem Cell Research in Full Swing in Israel
    • Key Players
  • B. Market Analytics
    • Table 40: Rest of World Recent Past, Current and Future Analysis for Mesenchymal Stem Cells Analyzed with Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 41: Rest of World Historic Review for Mesenchymal Stem Cells Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

COMPETITIVE LANDSCAPE

Back to Top